trial

An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms

NCTId NCT00161044
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 20
Sponsored by University of Maryland, Baltimore County
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
20
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2004-09
Primary completion
—
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Galantamine

Sponsors

University of Maryland, Baltimore CountyLead Sponsor

Investigators

1
Matthew Nelson, Pharm.D.Principal Investigator

Sites

1 total
Catonsville, United States

Facts & assertions

3 sourced
Enrollment
20
Phase
NA
Status
COMPLETED
relationships
The graph out of here
drug
Galantamine
drug
lead_sponsor
University of Maryland, Baltimore County
company
indication
Chronic Schizophrenia
indication
investigator
Matthew Nelson, Pharm.D.
person